Welcome to our dedicated page for Optimizerx SEC filings (Ticker: OPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OptimizeRx Corporation (OPRX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. OptimizeRx is a Nevada corporation listed on Nasdaq, and its filings include current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and related exhibits. These documents offer detailed information about the company’s financial condition, governance, executive changes, and material events.
Recent Form 8-K filings for OptimizeRx have covered topics such as leadership changes, board appointments, and the release of quarterly financial results. For example, the company has filed current reports describing the appointment of new executive officers, changes in responsibilities among senior leaders, and the addition of its chief executive officer to the board of directors. Other 8-K filings reference press releases that announce financial results for specific quarters, which are incorporated by reference into the filings.
Investors reviewing OptimizeRx’s periodic reports can examine how the company describes its healthcare technology platform, relationships with life sciences clients, and key performance indicators. Forms 10-K and 10-Q include audited or reviewed financial statements, discussions of risk factors, management’s analysis of results, and details about revenue composition and operating expenses. Together, these filings provide a structured view of how OptimizeRx reports its business performance and risks to regulators and shareholders.
On this page, Stock Titan also offers AI-powered summaries to help interpret lengthy filings such as 10-Ks and 10-Qs. These summaries are designed to highlight important sections, including revenue trends, balance sheet items, and disclosures about executive appointments or governance changes that appear in Forms 8-K. Users can also look for insider transaction reports on Form 4 and proxy materials on Schedule 14A, where available, to gain additional insight into ownership, compensation, and voting matters related to OPRX.
OptimizeRx Corporation (OPRX) filed an 8-K on June 24, 2025 to disclose a governance change. Effective June 20, 2025, the Board of Directors expanded from five to six members and appointed CEO Stephen Silvestro to fill the new seat. Silvestro will serve until the 2026 annual meeting, subject to earlier resignation or removal. No other executive departures, financial data, or strategic transactions were reported. The company furnished a related press release as Exhibit 99.1; the information in Item 7.01 is deemed “furnished,” not “filed,” under the Exchange Act.
Aside from this board adjustment, the 8-K contains no updates on earnings, guidance, or operations. Therefore, the filing is primarily informational and unlikely to have a material impact on valuation or near-term cash flows.